Bayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts of patients with known or suspected coronary artery disease (CAD). The magnetic resonance ...
They were especially interested to see if they accumulated in the kidney, as existing gadolinium-based contrast agents like ...
Zydus' agreement with Viwit Pharmaceuticals covers the supply of gadobutrol and gadoterate meglumine injections, widely used ...
Viwit will handle manufacturing and supply of the injectables, while Zydus Lifesciences will "exclusively market, distribute" and sell them.
Ahmedabad: Zydus Lifesciences Ltd., a global innovation driven healthcare company has announced that its wholly owned ...
Zydus Lifesciences announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit), an ...
The agreement includes the supply of gadobutrol injection, a generic version of Gadavist, and gadoterate meglumine injection, ...
Bayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts of patients with known or suspected coronary artery disease (CAD). The magnetic resonance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback